Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ALNY stock price vs DEO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DEO's multiple
Needs DEO P/E.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALNY FY 2025 (ended Dec 31, 2025) · DEO FY 2025 (ended Jun 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.82x
Capital structure 62% equity / 38% debt · EV / Revenue 3.05x · EV / EBITDA 23.15x
DEO carries the larger enterprise value at $85.25B against $38.08B; DEO trades on the lower EV / Revenue multiple (3.05x vs 10.25x); DEO on the lower EV / EBITDA (23.15x vs 63.82x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
DIAGEO plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
5.22x
—
Net debt / EBITDA
Leverage against operating earnings
4.13x
8.42x
Cash and equivalents
Liquid reserves on the balance sheet
$1.66B
$2.20B
Total debt
Interest-bearing obligations outstanding
$4.12B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ALNY vs MRNA
Sarepta Therapeutics, Inc.
ALNY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALNY vs VRTX
BioNTech SE
ALNY vs BNTX
ACADIA PHARMACEUTICALS INC
ALNY vs ACAD
CONSTELLATION BRANDS, INC.
ALNY vs STZ
COCA COLA CO
ALNY vs KO
PEPSICO INC
ALNY vs PEP
MOLSON COORS BEVERAGE CO
ALNY vs TAP
BOSTON BEER CO INC
ALNY vs SAM
$33.20B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
